Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 764532 in Glioma Expressing DLL3
NCT05916313Phase 1Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2024
- Primary completion
- Aug 2027
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Bispecific Antibodies
- Countries
- 6
01
Overview
Phase 1, open-label, single-arm trial of obrixtamig in glioma, sponsored by Boehringer Ingelheim. Primary endpoint: Dose-Limiting Toxicity at 4 weeks. Started Jan 2024; status: recruiting.
02
Drugs
obrixtamig
03
Conditions
glioma
Beyond the preview
Go deeper on NCT05916313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05916313.